Tag - SEOVF

Executive Moves

Sernova names Cynthia Pussinen as CEO

Sernova (TSX:SVA; OTCQB:SEOVF; FSE/XETRA:PSH) appointed Cynthia Pussinen as CEO and a member of the board, succeeding Dr. Philip Toleikis, who will serve as chief technology officer. Ms. Pussinen’s expertise spans...

September 5, 2023

Executive Moves

Sernova names Frank Shannon as VP clinical development, regulatory affairs

Frank Shannon Sernova (TSXV:SVA; OTC:SEOVF; FSE/XETRA:PSH) appointed 25-year pharmaceutical industry executive, Frank Shannon, as VP of clinical development and regulatory Affairs. Mr. Shannon most recently served...

June 30, 2021

Developments

Sernova’s Cell Pouch shows sustained clinical benefit in Type 1 diabetes

Sernova (TSXV:SVA; OTC:SEOVF; FSE:PSH) reported additional positive preliminary safety and efficacy data for its Cell Pouch transplanted with insulin producing cells in patients with Type 1 diabetes. Data presented at...

January 15, 2021

Feature

Sernova in clinical development for functional cure of Type 1 Insulin-dependent diabetes

Sernova’s (TSXV:SVA; OTCQB:SEOVF) Cell Pouch System, composed of an implantable device, therapeutic cells and immune protection technologies, has the potential to be a “functional cure” for millions of people with Type...

January 5, 2021

Developments

Sernova announces first islet cell transplant in Phase 1/2 Cell Pouch trial

Sernova (OTCQB:SEOVF) has performed its first Cell Pouch islet cell transplant in a Phase 1/2 study of Type 1 diabetes patients. Sernova’s Cell Pouch is a micro-encapsulation device that houses, supports, and protects...

April 11, 2019